Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multicenter, Open-Label Study of SQZ-AAC-HPV as Monotherapy and in Combination With Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1, Multicenter, Open-Label Study of SQZ-AAC-HPV as Monotherapy and in Combination With Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; SQZ-AAC-HPV (Primary)
  • Indications Anal cancer; Cervical cancer; Head and neck cancer; Penile cancer; Rectal cancer; Vulvovaginal cancer
  • Focus Adverse reactions
  • Acronyms ENVOY-001
  • Sponsors SQZ Biotech

    • Most Recent Events

    • 21 Feb 2024 Status changed from active, no longer recruiting to discontinued.
    • 03 Nov 2023 According to SQZ media release, data from this study presented at the Society for Immunotherapy of Cancer Annual Meeting 2023.
    • 03 Nov 2023 Results presented in a SQZ Biotech Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top